Congress quietly restores drug discounts for hospitals hit by Medicaid cuts

What it does

This bill creates a temporary exception to the 340B drug discount program's eligibility rules for hospitals that lost their status due to Medicaid payment cuts. Hospitals that were enrolled on July 3, 2025, but no longer meet the disproportionate-share-hospital (DSH) threshold because of declining Medicaid reimbursements can continue accessing discounted drugs through 2030. The bill also requires a study of how Medicaid cuts affect rural hospital services and payment formulas.

Why we flagged it

The operative mechanism is a narrow eligibility waiver for a defined cohort of hospitals (those enrolled as of July 3, 2025) to restore access to 340B drug discounts. The study requirement is a secondary accountability measure addressing rural hospital decline, but the primary function is sectoral relief.

• GAO study of DSH criteria, rural payment decline, and alternative payment formulas is substantively unrelated to the eligibility waiver itself; it is a policy-research rider addressing broader Medicaid payment reform.

What the text implies

• The waiver is time-limited (through Sept 30, 2030) but applies retroactively to cost-reporting periods beginning in FY 2026, creating a window where hospitals can recapture discounts they lost mid-fiscal-year due to Medicaid cuts.
• The bill does not require hospitals to pass drug-cost savings to patients, uninsured populations, or charity care; savings may accrue to hospital balance sheets or executive compensation.
• The study requirement focuses on rural hospital decline but does not mandate legislative action or appropriations to address findings, limiting its practical impact.
• Hospitals that lost DSH status due to Medicaid cuts but were NOT enrolled on July 3, 2025, remain ineligible, creating a cliff that may disadvantage newer or recently-restructured entities.
• The waiver applies only to the DSH-percentage requirement; hospitals must still meet all other 340B eligibility criteria, potentially excluding some hospitals that lost status on multiple grounds.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Hospitals regaining drug-discount access may lower uncompensated-care costs and preserve rural services (public benefit), but the bill does not directly cap patient costs or guarantee savings pass to patients; the study requirement adds transparency on rural hospital decline (accountability benefit), but the core mechanism is a narrow eligibility carve-out for a specific cohort of hospitals, not a broad public-health intervention.

Who stands to gain

• hospitals (nonprofit and for-profit)
• hospital systems
• rural health networks

Named in the bill

340B drug discount program, Public Health Service Act, Medicaid, disproportionate-share hospitals (DSH), Comptroller General of the United States, Medicare Payment Advisory Commission, American Hospital Association, America's Essential Hospitals, Children's Health Association, Social Security Administration

Where it stands

• Aug 20, 2026 — Introduced · Congress.gov: “Introduced in House”
• Aug 20, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.